Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epinastine ophthalmic - Allergan

Drug Profile

Epinastine ophthalmic - Allergan

Alternative Names: Alesion LX Ophthalmic Solution; Alesion Ophthalmic Solution; DE-114; DE-114A; Elestat; Epinastine eye drops; Epinastine hydrochloride; Epinastine hydrochloride high dose; Purivist; Relestat

Latest Information Update: 25 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Allergan; Santen Pharmaceutical
  • Class Antiallergics; Dibenzazepines; Eye disorder therapies; Imidazoles; Nonsedating antihistamines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Histamine H2 receptor antagonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic conjunctivitis

Most Recent Events

  • 20 Sep 2019 Santen Pharmaceutical signs a joint manufacturing and marketing agreement with Mitsubishi Tanabe Pharma Corporation for epinastine hydrochloride and high-dose epinastine hydrochloride (for treatment of Allergic conjunctivitis) in Japan
  • 20 Sep 2019 Registered for Allergic conjunctivitis in Japan (Ophthalmic)
  • 07 May 2019 Santen Pharmaceutical completes a clinical trial for Allergic conjunctivitis in Japan (UMIN000030789)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top